Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Wave Life Sciences (WVE) Change in Receivables (2018 - 2025)

Historic Change in Receivables for Wave Life Sciences (WVE) over the last 7 years, with Q3 2025 value amounting to $8.4 million.

  • Wave Life Sciences' Change in Receivables rose 74984.5% to $8.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 24285.71%. This contributed to the annual value of -$19.7 million for FY2024, which is 19325.62% down from last year.
  • Wave Life Sciences' Change in Receivables amounted to $8.4 million in Q3 2025, which was up 74984.5% from $1.6 million recorded in Q2 2025.
  • Wave Life Sciences' Change in Receivables' 5-year high stood at $14.1 million during Q4 2023, with a 5-year trough of -$37.5 million in Q3 2021.
  • Moreover, its 4-year median value for Change in Receivables was $1.3 million (2024), whereas its average is -$4.5 million.
  • As far as peak fluctuations go, Wave Life Sciences' Change in Receivables crashed by 11842.86% in 2024, and later skyrocketed by 74984.5% in 2025.
  • Wave Life Sciences' Change in Receivables (Quarter) stood at -$22.5 million in 2021, then soared by 162.6% to $14.1 million in 2023, then plummeted by 89.9% to $1.4 million in 2024, then skyrocketed by 489.52% to $8.4 million in 2025.
  • Its Change in Receivables stands at $8.4 million for Q3 2025, versus $1.6 million for Q2 2025 and -$1.4 million for Q1 2025.